Moffitt Cancer Center | Strategic Alliance Partners

January 19, 2024

Analyze risks and complications associated with allo-HSCT, including graft-versus-host disease, infections, relapse, and regimen-related toxicities.

January 19, 2024

This presentation will detail the supportive therapies and interventions provided to patients before, during, and after undergoing allo-HSCT. The speaker will also discuss management of treatment side effects and comorbidities to optimize patient outcomes.

January 19, 2024

Delve into the pre-transplant conditioning regimens such as chemotherapy and radiation used to prepare and immunosuppress patients to prevent graft rejection prior to allogeneic hematopoietic stem cell transplantation.

January 19, 2024

Faculty share insights into the overall strategy for managing relapsed/refractory CLL following first-line therapy with venetoclax-based regimens and BTK inhibitors, discussing strategy variations based on prior first-line treatments.

January 19, 2024

Experts explore the role of BTKi-based combination therapy in the front-line treatment of CLL, focusing on patient considerations and referencing key data from CAPTIVATE, FLAIR, MAJIC, and SEQUOIA (Arm D).

January 18, 2024

Iman Imanirad, MD, medical oncologist, gastrointestinal oncology, Moffitt Cancer Center, discusses the management of toxicities associated with standard-of-care encorafenib plus cetuximab for patients with previously treated microsatellite stable BRAF V600E metastatic colorectal cancer.

January 17, 2024

Richard Kim, MD, discusses ongoing and planned research at Moffitt Cancer Center in patients with hepatocellular carcinoma.

January 16, 2024

A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.

January 16, 2024

Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.

January 12, 2024

Richard Kim, MD, discusses selecting between frontline immunotherapy-based regimens in patients with hepatocellular carcinoma.

January 12, 2024

Javier Pinilla, MD, PhD, provides a brief overview of the changing CLL treatment landscape, discussing the influence of off-target adverse events and the development of treatment resistance on the evolution of BTK inhibitor therapy.

January 12, 2024

Joanna Rhodes, MD, MSCE, explores the general approach to treatment-naïve CLL patients with high-risk factors such as del17p and TP53 mutations.

January 12, 2024

Brian Hill, MD, PhD, discusses the use of BTK inhibitor monotherapy in CLL and presented recent long-term data updates from studies such as the 6-year follow-up of ELEVATE-TN and the extended follow-up from SEQUOIA.

January 11, 2024

Ariel Grajales-Cruz, MD, discusses real-world safety and efficacy outcomes with teclistamab in select patients with relapsed/refractory multiple myeloma.

January 11, 2024

Ciara Freeman, MD, PhD, outlines an analysis conducted to identify factors linked to CAR T-cell therapy response in patients with hematologic malignancies.

January 10, 2024

Michael Jain, MD, discusses the importance of evaluating the impact of lymphoma-associated CD39-positive T cells on CAR T-cell phenotypes.

January 10, 2024

Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.

January 10, 2024

Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.

January 09, 2024

Rachid Baz, MD, discusses the use of idecabtagene vicleucel vs standard regimens in triple-class–exposed, relapsed/refractory multiple myeloma.

January 09, 2024

Andrew Kuykendall, MD, discusses the efficacy of pelabresib plus ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.